Eli Lilly is spending up to $3.8 billion to buy vaccines in development for shingles, staph infections, and Epstein-Barr virus as well as the platform technologies that spawned these programs. The pharmaceutical giant indicated interest in infectious disease last year when it hired Peter Marks, former director of the FDA division that oversees vaccines.
The post Eli Lilly’s Vaccine Acquisitions Signal a Strategy of Growth in New Areas appeared first on MedCity News.
CrowdStrike disrupts Glassworm botnet targeting developers – SecurityBrief Australia
CrowdStrike disrupts Glassworm botnet targeting developers SecurityBrief Australia
